Interview with the executive director of Recce Pharmaceuticals, James Graham. Recce Pharmaceutical is listed on the ASX with the ticker RCE.
Interview Timestamps:
(02:00) Introduction to Recce Pharmaceuticals
(03:40) Clinical Trials with Parexel
(06:20) COVID-19's impact on the business
(09:50) R&D rebates in Australia
(11:10) Investors engagement
(12:45) Introduction to the team
(14:20) Definition of success for Recce Pharmaceuticals
Disclaimer:
Do note that our content is intended to be used and must be used for informational purposes only. Under no circumstances does the information presented in this podcast represent a buy, sell or hold recommendation on any security. This podcast does not constitute accounting, legal, tax, or other professional advice. Listeners should not act upon the content or information found here without first seeking appropriate advice from an accountant, financial planner, lawyer or other professional.
We give no assurance or warranty regarding the accuracy, timeliness, or applicability of any of the contents. We assume no responsibility for information contained on this website and disclaim all liability in respect of such information, including but not limited to any liability for errors, inaccuracies, omissions, or misleading or defamatory statements.
Listening to this podcast constitutes an explicit understanding and acceptance of the terms of this disclaimer.
#ASX #Interviews #CEO #Investing #Business